Catalyst Wire Dossier Catalyst Wire Dossier

GNR-127

· AO Generium
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for GNR-127, covering 2025-09-04 to 2025-09-04. Get the full timeline:

Most recent: Clinical Trial Update: A Clinical Trial for Evaluation of Efficacy, Safety and Immunogenicity of GNR-127 (Recombinant ABP Antigen Protein Which Carries a Birch Pollen Allergen [BET V 1] and an Apple Allergen [MAL D 1]) in Patients With Birch Pollen Allergic Rhinitis. [Phase 1, Phase 2]

See pricing